HIV Vaccine Development and Clinical Trails

Dear Colleagues,

The HIV pandemic still remains a burden for many people worldwide. In 2022, approximately 1.3 million new HIV infections were recorded globally, yet only 76% of people living with the virus had access to antiretroviral therapy in that same year. It is clear that the development of an effective anti-HIV vaccine will be essential to control the HIV pandemic. Pre-clinical and clinical studies conducted in animals and human volunteers are pivotal to develop novel anti-HIV vaccine strategies and to test their safety and immunogenicity.

Vaccines is a peer-reviewed international journal focused on clinical vaccine research, utilization, and immunization and we are pleased to invite you to submit your manuscripts to one of this journal’s Special Issue titled ‘HIV Vaccine Development and Clinical Trials.’

The aim of this Special Issue is to share pre-clinical and clinical studies pertaining to new anti-HIV vaccine technologies, improvement in already tested anti-HIV vaccines, and the implementation of novel strategies, such as the use of different immunogens or adjuvants, to increase the immune responses elicited by anti-HIV vaccines. 

We welcome both original research articles and reviews. Research areas may include (but not limited to) the following:

• Development of novel anti-HIV vaccines and immunogens;
• Development of novel adjuvants in the contest of anti-HIV vaccines;
• Induction of anti-HIV broadly neutralizing antibodies;
• Testing of novel anti-HIV vaccines in preclinical studies in animal models;
• Testing of novel anti-HIV vaccines in clinical trials in human volunteers;
• Development of assays to investigate immune responses to anti-HIV vaccination;
• Investigation of immune correlates of protection in preclinical and clinical studies.

We look forward to receiving your contributions.

Dr. Massimiliano Bissa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• HIV vaccine
• HIV vaccine clinical trial
• HIV vaccine adjuvant
• correlate of decreased HIV risk
• HIV immunogen
• broadly neutralizing antibodies